• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

内耳道内前庭神经鞘瘤患者的听力情况

Hearing in patients with intracanalicular vestibular schwannomas.

作者信息

Caye-Thomasen Per, Dethloff Thomas, Hansen Søren, Stangerup Sven-Eric, Thomsen Jens

机构信息

Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Gentofte University Hospital of Copenhagen, Copenhagen, Denmark.

出版信息

Audiol Neurootol. 2007;12(1):1-12. doi: 10.1159/000096152. Epub 2006 Oct 10.

DOI:10.1159/000096152
PMID:17033159
Abstract

This paper reports data on the spontaneous course of hearing in 156 patients with purely intracanalicular vestibular schwannomas. The mean pure tone average (PTA) was 51 dB HL and the mean speech discrimination score (SDS) 60% at diagnosis. The risk of a significant subsequent hearing loss (>or=10 dB PTA or >or=10% SDS) was 54% during 4.6 years of observation. Patients with normal speech discrimination at diagnosis had a significantly smaller risk of loosing hearing. The hearing loss at diagnosis and during observation was not related to age, gender, diagnostic tumor size, tumor- induced expansion of the internal auditory canal or tumor sublocalization (fundus, central or porus). However, the loss of PTA was smaller in shrinking tumors and the PTA deterioration rate correlated with the volumetric tumor growth rate. After 4.6 years observation, the PTA had increased by 14 dB to 65 dB HL, and the SDS reduced by 17% to 43%. The proportion of patients eligible for hearing preservation treatment as determined by word recognition score class I (70-100% SDS) was reduced to 28% (a 44% reduction), and by AAO-HNS class A to 9% (a 53% reduction).

摘要

本文报告了156例纯内听道型前庭神经鞘瘤患者听力的自然病程数据。诊断时平均纯音听阈(PTA)为51dB HL,平均言语识别率(SDS)为60%。在4.6年的观察期内,随后出现显著听力损失(PTA≥10dB或SDS≥10%)的风险为54%。诊断时言语识别正常的患者听力丧失风险显著较小。诊断时及观察期间的听力损失与年龄、性别、诊断时肿瘤大小、肿瘤引起的内听道扩大或肿瘤定位(底部、中央或孔口)无关。然而,肿瘤缩小的患者PTA损失较小,且PTA恶化率与肿瘤体积生长率相关。经过4.6年的观察,PTA增加了14dB至65dB HL,SDS降低了17%至43%。根据言语识别评分I级(SDS 70 - 100%)确定适合听力保留治疗的患者比例降至28%(降低了44%),根据美国耳鼻咽喉头颈外科学会(AAO - HNS)A类标准降至9%(降低了53%)。

相似文献

1
Hearing in patients with intracanalicular vestibular schwannomas.内耳道内前庭神经鞘瘤患者的听力情况
Audiol Neurootol. 2007;12(1):1-12. doi: 10.1159/000096152. Epub 2006 Oct 10.
2
Consequences to hearing during the conservative management of vestibular schwannomas.前庭神经鞘瘤保守治疗期间的听力后果。
Laryngoscope. 2000 Feb;110(2 Pt 1):250-5. doi: 10.1097/00005537-200002010-00012.
3
Cochlear origin of early hearing loss in vestibular schwannoma.前庭神经鞘瘤早期听力损失的耳蜗起源
Laryngoscope. 2007 Apr;117(4):680-3. doi: 10.1097/MLG.0b013e31803146c5.
4
The risk of hearing loss in nongrowing, conservatively managed acoustic neuromas.非生长型、保守治疗的听神经瘤患者的听力损失风险。
Am J Otol. 1999 Nov;20(6):758-62.
5
Sublocalization and volumetric growth pattern of intracanalicular vestibular schwannomas.管内型前庭神经鞘瘤的亚定位及体积生长模式
Laryngoscope. 2006 Jul;116(7):1131-5. doi: 10.1097/01.MLG.0000217528.37106.2D.
6
Sensorineural hearing loss after occlusion of the enlarged vestibular aqueduct.扩大的前庭导水管闭塞后导致的感音神经性听力损失
Am J Otol. 1999 May;20(3):338-43.
7
Gamma knife radiosurgery for vestibular schwannomas: results of hearing preservation in relation to the cochlear radiation dose.伽玛刀放射外科治疗前庭神经鞘瘤:与耳蜗辐射剂量相关的听力保留结果
Laryngoscope. 2009 Jun;119(6):1076-81. doi: 10.1002/lary.20245.
8
Correlation of hearing loss and radiologic dimensions of vestibular schwannomas (acoustic Neuromas).听力损失与前庭神经鞘瘤(听神经瘤)的放射学尺寸的相关性
Am J Otol. 1996 Mar;17(2):312-6.
9
Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy.全身治疗失败后鼓室内注射地塞米松治疗突发性感音神经性听力损失
Laryngoscope. 2007 Jan;117(1):3-15. doi: 10.1097/01.mlg.0000245058.11866.15.
10
Tumor growth and audiometric change in vestibular schwannomas managed conservatively.保守治疗的前庭神经鞘瘤的肿瘤生长及听力测定变化
Laryngoscope. 2000 Nov;110(11):1843-9. doi: 10.1097/00005537-200011000-00015.

引用本文的文献

1
Angiotensin-Receptor Blockers Prevent Vestibular Schwannoma-Associated Hearing Loss.血管紧张素受体阻滞剂可预防前庭神经鞘瘤相关听力损失。
Otol Neurotol. 2025 Feb 1;46(2):183-189. doi: 10.1097/MAO.0000000000004376.
2
A Proposal for Comprehensive Audio-Vestibular Test Battery Protocol for Diagnosis and Follow-Up Monitoring in Patients with Vestibular Schwannoma Undergoing Surgical Tumor Removal.一项关于听神经瘤手术切除患者诊断及随访监测的综合听-前庭测试组合方案的提议。
J Clin Med. 2024 Aug 23;13(17):5007. doi: 10.3390/jcm13175007.
3
Reported Hearing Outcome Measures Following Stereotactic Radiosurgery for Vestibular Schwannoma: A Scoping Review.
立体定向放射外科治疗前庭神经鞘瘤后的听力结果测量报告:一项范围综述
J Neurol Surg B Skull Base. 2023 Feb 22;85(2):123-130. doi: 10.1055/a-2021-8762. eCollection 2024 Apr.
4
miR-431 secreted by human vestibular schwannomas increases the mammalian inner ear's vulnerability to noise trauma.人类前庭神经鞘瘤分泌的miR-431增加了哺乳动物内耳对噪声损伤的易感性。
Front Neurol. 2023 Oct 9;14:1268359. doi: 10.3389/fneur.2023.1268359. eCollection 2023.
5
The genetic landscape and possible therapeutics of neurofibromatosis type 2.2型神经纤维瘤病的遗传图谱及可能的治疗方法。
Cancer Cell Int. 2023 May 23;23(1):99. doi: 10.1186/s12935-023-02940-8.
6
Sporadic Vestibular Schwannoma Size and Location Do not Correlate With the Severity of Hearing Loss at Initial Presentation.散发性前庭神经鞘瘤的大小和位置与初次就诊时听力损失的严重程度无关。
Front Oncol. 2022 Mar 15;12:836504. doi: 10.3389/fonc.2022.836504. eCollection 2022.
7
Tumor-Associated Macrophages in Vestibular Schwannoma and Relationship to Hearing.前庭神经鞘瘤中的肿瘤相关巨噬细胞及其与听力的关系
OTO Open. 2021 Nov 23;5(4):2473974X211059111. doi: 10.1177/2473974X211059111. eCollection 2021 Oct-Dec.
8
Current Understanding of Hearing Loss in Sporadic Vestibular Schwannomas: A Systematic Review.散发性前庭神经鞘瘤听力损失的当前认识:一项系统综述。
Front Oncol. 2021 Aug 12;11:687201. doi: 10.3389/fonc.2021.687201. eCollection 2021.
9
Optimized preoperative determination of nerve of origin in patients with vestibular schwannoma.前庭神经鞘瘤患者起源神经的术前优化判定
Sci Rep. 2021 Apr 21;11(1):8608. doi: 10.1038/s41598-021-87515-1.
10
New developments in neurofibromatosis type 2 and vestibular schwannoma.2型神经纤维瘤病和前庭神经鞘瘤的新进展。
Neurooncol Adv. 2020 Nov 16;3(1):vdaa153. doi: 10.1093/noajnl/vdaa153. eCollection 2021 Jan-Dec.